Activating mutations in the proto-oncogene KRAS are a hallmark of pancreatic ductal adenocarcinoma (PDAC), an aggressive malignancy with few effective therapeutic options. This evidence concerns the gene KRAS and pancreatic ductal adenocarcinoma.